# China NMPA Drug Inspection - Pfizer Pharmaceuticals Co., Ltd. - Azithromycin dry suspension

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/pfizer-pharmaceuticals-co-ltd/19b11187-c058-40a8-b1f6-3348a26936e6/
Source feed: China

> China NMPA drug inspection for Pfizer Pharmaceuticals Co., Ltd. published September 09, 2021. Drug: Azithromycin dry suspension. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Information Bulletin on Drug Quality Sampling Inspection in Qinghai Province (Issue 1, 2021)
- Company Name: Pfizer Pharmaceuticals Co., Ltd.
- Publication Date: 2021-09-09
- Drug Name: Azithromycin dry suspension
- Inspection Finding: qualified

Company: https://www.globalkeysolutions.net/companies/pfizer-pharmaceuticals-co-ltd/8b1407a5-b939-468d-a383-a7c7069b2207/